SPCC553.06 Antibody

What is SPCC553.06 Antibody and what organism does it target?

SPCC553.06 Antibody is a polyclonal antibody raised in rabbits that specifically targets the SPCC553.06 protein from Schizosaccharomyces pombe (strain 972 / ATCC 24843), commonly known as fission yeast. This antibody recognizes epitopes on the protein encoded by the SPCC553.06 gene (UniProt accession number O74943). The antibody is produced through immunization with a recombinant form of the target protein and is subsequently purified using antigen affinity methods to ensure high specificity in experimental applications .

What are the typical applications for SPCC553.06 Antibody in research?

SPCC553.06 Antibody has been validated for use in enzyme-linked immunosorbent assay (ELISA) and Western blotting (WB) techniques. These applications enable researchers to detect and quantify the presence of the target protein in various experimental samples. The antibody's specificity makes it particularly valuable for studying protein expression patterns, localization, and interactions in fission yeast models . Like other research antibodies, its applications build on the fundamental principles of antibody-antigen recognition that form the basis of many immunological techniques used in molecular and cellular biology research .

How should SPCC553.06 Antibody be stored to maintain its activity?

For optimal preservation of activity, SPCC553.06 Antibody should be stored at either -20°C or -80°C immediately upon receipt. Repeated freeze-thaw cycles should be avoided as they can lead to denaturation and aggregation of antibody molecules, potentially compromising binding affinity and specificity. The antibody is supplied in a storage buffer containing 0.03% Proclin 300 (as a preservative) and 50% glycerol in 0.01M PBS at pH 7.4, which helps maintain stability during freezing . This storage approach aligns with general best practices for preserving antibody function, as inappropriate storage conditions can lead to diminished performance in downstream applications .

What controls should be included when using SPCC553.06 Antibody in Western blotting experiments?

When designing Western blotting experiments with SPCC553.06 Antibody, several critical controls should be incorporated:

• Positive control: Lysate from wild-type S. pombe cells known to express the SPCC553.06 protein

• Negative control: Lysate from S. pombe strains with SPCC553.06 gene deletion

• Loading control: Probing for a constitutively expressed protein (e.g., actin or tubulin)

• Secondary antibody control: Membrane incubated with only the secondary antibody to assess non-specific binding

• Blocking control: Testing different blocking reagents to optimize signal-to-noise ratio

These controls help validate antibody specificity and experimental reliability . Because this is a polyclonal antibody, lot-to-lot variation may occur, making proper controls particularly important for experimental reproducibility .

How can optimal dilution ratios be determined for SPCC553.06 Antibody in different applications?

Determining optimal dilution ratios for SPCC553.06 Antibody requires systematic titration experiments for each application:

For Western blotting:

• Prepare a dilution series (e.g., 1:500, 1:1000, 1:2000, 1:5000) of the antibody

• Run identical protein samples on multiple blots

• Process each blot with a different antibody dilution

• Compare signal intensity and background levels

• Select the dilution that provides the best signal-to-noise ratio

For ELISA:

• Prepare a standard curve with known concentrations of recombinant SPCC553.06 protein

• Test antibody dilutions ranging from 1:100 to 1:10,000

• Calculate signal-to-noise ratios for each dilution

• Choose the dilution that provides optimal sensitivity and specificity

This methodical approach follows standard practices for antibody optimization in immunoassays and helps ensure reliable, reproducible results .

What sample preparation methods are recommended when working with SPCC553.06 Antibody?

Effective sample preparation for SPCC553.06 Antibody applications involves several critical steps:

• Cell lysis: For S. pombe cells, use glass bead disruption in buffer containing protease inhibitors to prevent protein degradation

• Protein extraction: Employ buffer conditions that maintain native protein conformation (e.g., Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100)

• Denaturation for Western blotting: Heat samples at 95°C for 5 minutes in Laemmli buffer containing SDS and β-mercaptoethanol

• Protein quantification: Use Bradford or BCA assay to ensure equal loading

• Sample storage: Aliquot samples to avoid freeze-thaw cycles and store at -80°C

When working with membrane proteins or proteins prone to aggregation, optimization of detergent types and concentrations may be necessary to maximize extraction efficiency while preserving antibody recognition sites .

How can SPCC553.06 Antibody be utilized for studying protein-protein interactions in fission yeast?

SPCC553.06 Antibody can be employed in several sophisticated approaches to investigate protein-protein interactions:

• Co-immunoprecipitation (Co-IP):

  • Lyse S. pombe cells under non-denaturing conditions

  • Incubate lysate with SPCC553.06 Antibody conjugated to magnetic or agarose beads

  • Wash to remove non-specific interactions

  • Elute bound protein complexes and analyze by mass spectrometry

• Proximity Ligation Assay (PLA):

  • Fix S. pombe cells and permeabilize

  • Incubate with SPCC553.06 Antibody and an antibody against a suspected interaction partner

  • Apply oligonucleotide-conjugated secondary antibodies

  • When proteins are in close proximity, oligonucleotides hybridize and are amplified

  • Detect amplification products by fluorescence microscopy

• Chromatin Immunoprecipitation (ChIP):

  • If SPCC553.06 protein has nuclear functions, use the antibody to identify DNA-binding sites

These advanced applications extend beyond simple detection to reveal functional aspects of the target protein, though each requires careful optimization and validation .

What approaches can be used to validate the specificity of SPCC553.06 Antibody in complex experimental systems?

Validating antibody specificity is crucial for reliable research outcomes. For SPCC553.06 Antibody, consider these advanced validation approaches:

• Gene knockout/knockdown comparison:

  • Compare immunoblot/immunostaining patterns between wild-type cells and SPCC553.06 deletion mutants

  • Expected result: Signal should be absent or significantly reduced in knockout samples

• Preabsorption test:

  • Preincubate the antibody with excess purified recombinant SPCC553.06 protein

  • Apply preabsorbed antibody in parallel with untreated antibody

  • Expected result: Preabsorption should eliminate specific signals

• Mass spectrometry validation:

  • Immunoprecipitate with SPCC553.06 Antibody

  • Analyze precipitated proteins by mass spectrometry

  • Confirm presence of SPCC553.06 protein and characterize any co-precipitating proteins

• Orthogonal detection methods:

  • Compare results with alternative detection methods like RNA-seq or proteomics

  • Cross-validate with antibodies targeting different epitopes of the same protein

These rigorous validation approaches follow principles of antibody characterization established for therapeutic antibody development but applied to research contexts .

How can epitope mapping be performed to characterize SPCC553.06 Antibody binding sites?

Epitope mapping for SPCC553.06 Antibody can be accomplished through several methodological approaches:

• Peptide array analysis:

  • Synthesize overlapping peptides (15-20 amino acids) covering the entire SPCC553.06 protein sequence

  • Immobilize peptides on a membrane or chip

  • Probe with SPCC553.06 Antibody

  • Detect binding to identify specific peptides containing epitopes

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS):

  • Expose the protein to deuterium-containing buffer

  • Monitor deuterium incorporation rates with and without antibody binding

  • Regions protected from exchange upon antibody binding indicate epitope locations

• Mutagenesis approach:

  • Generate point mutations in recombinant SPCC553.06 protein

  • Test antibody binding to mutated proteins

  • Amino acid substitutions that abolish binding identify critical epitope residues

Since SPCC553.06 Antibody is polyclonal, epitope mapping will likely reveal multiple binding sites, providing insight into the diversity of recognition sites and potentially guiding the development of more specific monoclonal versions .

What strategies can address weak or absent signals when using SPCC553.06 Antibody in Western blotting?

When facing signal detection issues with SPCC553.06 Antibody in Western blotting, implement these methodological solutions:

• Sample preparation optimization:

  • Ensure complete lysis of S. pombe cells (which have tough cell walls)

  • Try different lysis buffers to improve protein extraction

  • Add phosphatase inhibitors if phosphorylation affects epitope recognition

• Blocking and antibody incubation:

  • Test alternative blocking agents (5% BSA may be superior to milk for some applications)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Reduce washing stringency to preserve weak interactions

• Detection system enhancement:

  • Switch to more sensitive detection methods (e.g., chemiluminescence to enhanced chemiluminescence)

  • Use signal amplification systems (e.g., biotin-streptavidin)

  • Consider longer exposure times for film-based detection

• Transfer optimization:

  • For high molecular weight proteins, extend transfer time or use different buffer systems

  • For hydrophobic proteins, adjust methanol content in transfer buffer

A systematic approach to troubleshooting, changing one variable at a time, helps identify the specific limitation in your experimental setup .

How can non-specific binding be reduced when using SPCC553.06 Antibody?

Non-specific binding can significantly impact experimental interpretation. To minimize this problem with SPCC553.06 Antibody:

• Optimization of blocking conditions:

  Blocking Agent	Concentration	Incubation Time	Best For
  BSA	3-5%	1-2 hours	Phosphoprotein detection
  Non-fat milk	5%	1 hour	General applications
  Casein	1%	1-2 hours	Low background for fluorescent detection
  Commercial blockers	As directed	As directed	Specialized applications

• Antibody dilution optimization:

  • Testing higher dilutions may reduce non-specific binding while maintaining specific signal

  • Consider using antibody diluents containing low concentrations of detergents (0.05% Tween-20)

• Washing protocol enhancement:

  • Increase number of washes (5-6 times for 5 minutes each)

  • Use buffers with higher salt concentration (up to 500 mM NaCl) to disrupt weak, non-specific interactions

  • Add 0.1-0.2% SDS to wash buffer for stubborn background

• Preabsorption with irrelevant proteins:

  • Incubate antibody with S. cerevisiae lysate (related but different yeast species) before use

  • This can reduce cross-reactivity to conserved epitopes

These approaches are based on established principles for improving signal specificity in immunological techniques .

What factors should be considered when optimizing SPCC553.06 Antibody performance in different buffer systems?

Buffer composition significantly affects antibody-antigen interactions. For optimizing SPCC553.06 Antibody performance:

• pH optimization:

  • Test buffers ranging from pH 6.0-8.0

  • Antibody-antigen binding is typically optimal near physiological pH (7.2-7.4)

  • Minor pH adjustments can dramatically improve signal intensity

• Salt concentration effects:

  NaCl Concentration	Effect on Binding
  <100 mM	May increase non-specific interactions
  150 mM	Physiological; good starting point
  300-500 mM	Can reduce non-specific binding but may decrease affinity

• Detergent considerations:

  • Low concentrations (0.05-0.1%) of Tween-20 typically reduce background

  • For membrane proteins, mild detergents like digitonin or CHAPS may better preserve epitopes

  • Ionic detergents can denature proteins, potentially affecting epitope recognition

• Additives to consider:

  • 5-10% glycerol can stabilize antibodies during incubation

  • 1-5 mM EDTA may improve results if metalloprotease activity is present

  • 0.1-1% carrier proteins (BSA, casein) can prevent non-specific binding

Systematic optimization using a matrix approach allows identification of ideal buffer conditions for specific experimental setups .

How does SPCC553.06 Antibody compare with other antibodies targeting fission yeast proteins?

When comparing SPCC553.06 Antibody with other S. pombe-specific antibodies, several factors merit consideration:

• Specificity profiles:

  • As a polyclonal antibody, SPCC553.06 Antibody recognizes multiple epitopes, potentially providing robust detection but increased risk of cross-reactivity

  • Monoclonal antibodies against other S. pombe proteins offer higher specificity but may be more sensitive to epitope masking

• Application versatility:

  • SPCC553.06 Antibody is validated for ELISA and WB applications

  • Some commercially available antibodies against other fission yeast proteins have broader application profiles including immunohistochemistry and immunofluorescence

• Species cross-reactivity:

  • Antibodies against highly conserved proteins may exhibit cross-reactivity with related species

  • SPCC553.06 Antibody is specifically raised against fission yeast protein with specificity for this organism

• Performance characteristics:

  Antibody Type	Sensitivity	Specificity	Batch-to-Batch Consistency	Cost Considerations
  SPCC553.06 Polyclonal	High	Moderate	May vary between lots	Moderate
  Typical S. pombe monoclonal	Moderate	High	Consistent	Higher
  Tagged protein detection	Very high	Excellent	Highly consistent	Variable

This comparative analysis helps researchers select appropriate antibodies based on specific experimental requirements and available resources .

What bioinformatic approaches can predict epitopes recognized by SPCC553.06 Antibody?

Computational prediction of epitopes can provide valuable insights prior to experimental validation:

• Sequence-based epitope prediction:

  • B-cell epitope prediction algorithms (BepiPred, ABCpred) can identify potential linear epitopes

  • Analysis of hydrophilicity, flexibility, accessibility, and antigenicity profiles

  • For SPCC553.06 protein, regions with high surface probability scores are likely antibody targets

• Structural epitope prediction:

  • If 3D structure of SPCC553.06 protein is available or can be modeled:

    • Ellipro algorithm identifies protruding regions likely to be antigenic

    • DiscoTope predicts discontinuous B-cell epitopes

    • PEPOP can predict epitopes and guide peptide design

• Integrative approach workflow:

  • Generate protein structure prediction using AlphaFold

  • Identify surface-exposed residues

  • Calculate epitope propensity scores

  • Cross-reference with sequence conservation analysis

• Machine learning methods:

  • Deep learning approaches combining sequence and structural features

  • Support vector machines trained on validated epitope datasets

These computational approaches provide theoretical foundation for experimental epitope mapping and can guide the development of next-generation antibodies with enhanced specificity .

How can SPCC553.06 Antibody be integrated into multi-omics research approaches?

Integration of SPCC553.06 Antibody into multi-omics research frameworks enables comprehensive understanding of biological systems:

• Proteogenomic integration:

  • Combine RNA-seq data on SPCC553.06 expression with protein detection by the antibody

  • Correlate transcriptomic changes with protein abundance

  • Investigate post-transcriptional regulation mechanisms

• Protein interactome mapping:

  • Use SPCC553.06 Antibody for immunoprecipitation followed by mass spectrometry

  • Integrate with yeast two-hybrid or BioID proximity labeling data

  • Construct protein interaction networks centered on SPCC553.06 protein

• Functional genomics correlation:

  • Compare phenotypes of SPCC553.06 deletion/mutation with protein localization/abundance

  • Integrate ChIP-seq data (if SPCC553.06 has DNA-binding properties) with transcriptomics

  • Map protein function to specific cellular pathways

• Temporal dynamics studies:

  • Monitor SPCC553.06 protein levels during cell cycle or stress responses

  • Correlate with global proteome and phosphoproteome changes

  • Develop predictive models of protein behavior under different conditions

This integrative approach leverages the specificity of antibody-based detection within the broader context of systems biology, providing deeper insights than any single methodology .

What emerging technologies might enhance SPCC553.06 Antibody applications in future research?

Several cutting-edge technologies hold promise for expanding SPCC553.06 Antibody applications:

• Single-cell proteomics integration:

  • Adapting SPCC553.06 Antibody for mass cytometry (CyTOF)

  • Development of ultra-sensitive detection methods for single-cell Western blotting

  • Integration with microfluidic platforms for high-throughput single-cell analysis

• Spatial proteomics advances:

  • Optimization for multiplexed immunofluorescence using spectral unmixing

  • Application in Imaging Mass Cytometry for subcellular localization

  • CODEX (CO-Detection by indEXing) for highly multiplexed protein detection

• Nanobody and recombinant antibody development:

  • Engineering smaller antibody fragments against SPCC553.06 for improved tissue penetration

  • CRISPR-based epitope tagging combined with validated antibodies for enhanced specificity

  • Generating site-specific monoclonal antibodies for distinct functional domains

• Live-cell applications:

  • Development of cell-permeable antibody formats

  • Integration with optogenetic approaches for spatiotemporal protein monitoring

  • Combination with genomically encoded tags for correlative light and electron microscopy

These technological advancements promise to extend the utility of research antibodies beyond traditional applications, enabling more sophisticated exploration of protein dynamics and function .

How might understanding SPCC553.06 protein contribute to broader research in eukaryotic cell biology?

Research using SPCC553.06 Antibody may contribute to fundamental understanding of eukaryotic biology:

• Evolutionary conservation studies:

  • Investigating functional homologs across species

  • Understanding conserved protein domains and their significance

  • Tracing evolutionary adaptations in protein structure and function

• Cellular process insights:

  • If SPCC553.06 participates in core cellular processes, findings may translate to other eukaryotes

  • S. pombe as a model system often provides insights applicable to human cell biology

  • Discoveries may illuminate conserved regulatory mechanisms

• Methodology development:

  • Optimization techniques for this antibody may inform approaches for other challenging proteins

  • Novel applications could establish new protocols applicable to other research areas

  • Bioinformatic prediction methods developed for this system may have broader utility

• Translational potential:

  • Insights into fundamental processes may inform understanding of human disease mechanisms

  • Novel protein interactions discovered may represent potential therapeutic targets

  • Understanding protein modifications may illuminate regulatory networks conserved in humans

This broader perspective emphasizes the value of basic research with model organisms and specific molecular tools in advancing our understanding of fundamental biological principles .

What methodological advances could improve the developability and performance of next-generation antibodies against SPCC553.06?

Future improvements in antibody technology could enhance research capabilities:

• Advanced immunization strategies:

  • Using structural information to design immunogens exposing critical epitopes

  • Prime-boost strategies with different protein forms to broaden epitope recognition

  • Genetic immunization approaches for difficult-to-express proteins

• Selection and screening enhancements:

  • High-throughput screening methods to identify antibodies with superior properties

  • Application of machine learning for predicting antibody developability from sequence

  • Integration of developability assessments early in selection process

• Engineering for improved properties:

  Property	Enhancement Approach	Expected Benefit
  Specificity	Directed evolution or CDR engineering	Reduced cross-reactivity
  Affinity	Affinity maturation through display technologies	Improved detection sensitivity
  Stability	Framework optimization and aggregation hotspot removal	Extended shelf-life and consistency
  Functionality	Fc engineering or recombinant formats	Application-specific improvements

• Production and purification advances:

  • Optimized expression systems for consistent antibody production

  • Novel purification strategies to enhance yield and quality

  • Formulation improvements for better stability and reduced background

These methodological advances build on established antibody development principles while incorporating cutting-edge technologies to create next-generation research tools with enhanced performance characteristics .

What are the key considerations for experimental reproducibility when using SPCC553.06 Antibody?

Ensuring reproducible results with SPCC553.06 Antibody requires attention to several critical factors:

• Antibody validation and documentation:

  • Verify antibody specificity through appropriate controls

  • Document lot number and source for all experiments

  • Consider creating validation datasets specific to your experimental system

• Standardized protocols:

  • Develop detailed SOPs for all applications

  • Include precise timing, temperatures, and reagent compositions

  • Maintain consistent sample preparation methods

• Quantitative approach:

  • Use appropriate quantification methods for Western blots or ELISA

  • Include standard curves where applicable

  • Apply statistical analysis to replicate experiments

• Transparent reporting:

  • Document all experimental conditions and antibody details in publications

  • Report negative results and limitations

  • Share protocols through repositories or supplementary materials

Adherence to these best practices aligns with emerging standards for antibody use in research and supports the broader scientific community's efforts to enhance reproducibility .

How should researchers approach the integration of SPCC553.06 Antibody with complementary detection methods?

A multi-modal approach to protein detection provides stronger evidence and more comprehensive insights:

• Orthogonal validation strategy:

  • Complement antibody-based detection with mass spectrometry

  • Correlate protein levels with mRNA expression data

  • Use fluorescent protein tagging as an independent verification method

• Method selection based on research questions:

  Research Question	Primary Method	Complementary Method
  Protein abundance	Western blot with SPCC553.06 Antibody	Mass spectrometry quantification
  Protein localization	Immunofluorescence	Fractionation followed by Western blot
  Protein-protein interactions	Co-IP with SPCC553.06 Antibody	Proximity ligation assays
  Protein modifications	IP followed by modification-specific detection	Mass spectrometry

• Data integration approach:

  • Develop normalization strategies across different detection methods

  • Apply computational tools to integrate multi-modal data

  • Consider relative strengths and limitations of each method during interpretation

• Sequential application workflow:

  • Use SPCC553.06 Antibody for initial screening or hypothesis generation

  • Follow with orthogonal methods for validation

  • Apply specialized techniques for detailed mechanistic studies

This integrated approach maximizes the strengths of each methodology while mitigating their individual limitations .

What metrics should researchers use to evaluate the quality and reliability of SPCC553.06 Antibody in their specific experimental context?

Systematic evaluation of antibody performance is essential for reliable research outcomes:

• Specificity metrics:

  • Signal ratio between positive and negative controls

  • Band pattern comparison with predicted molecular weight

  • Signal reduction in knockout/knockdown samples

  • Cross-reactivity assessment with related proteins

• Sensitivity parameters:

  • Limit of detection (lowest amount of target protein detectable)

  • Dynamic range (linear range of signal vs. protein concentration)

  • Signal-to-noise ratio at working dilution

  • Reproducibility between technical and biological replicates

• Application-specific quality indicators:

  Application	Key Quality Metrics	Acceptance Criteria
  Western blot	Band specificity, background levels	Single band at expected MW, minimal background
  ELISA	Standard curve linearity, blank value	R² > 0.98, blank OD < 0.1
  IP	Enrichment factor, non-specific binding	>10x enrichment, minimal contaminants

• Batch-to-batch consistency evaluation:

  • Comparison of performance between lots

  • Antibody titration curves for each batch

  • Epitope mapping confirmation when available

These rigorous quality metrics enable researchers to objectively assess antibody performance and make informed decisions about experimental design and data interpretation .